Court ruling

The Supreme Court ruling on the Glivec patent case will allow generic firms to market their version of the medicine at a price 15 times lower than that charged by Novartis. Photo: Bloomberg<br />

Glivec and the question of innovation

4 min read . 08 Apr 2013